Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Receivables (2016 - 2025)

Immucell (ICCC) has disclosed Receivables for 16 consecutive years, with $2.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables rose 11.44% year-over-year to $2.6 million, compared with a TTM value of $2.6 million through Sep 2025, up 11.44%, and an annual FY2024 reading of $3.8 million, up 71.3% over the prior year.
  • Receivables was $2.6 million for Q3 2025 at Immucell, up from $2.4 million in the prior quarter.
  • Across five years, Receivables topped out at $3.8 million in Q4 2024 and bottomed at $1.4 million in Q2 2022.
  • Average Receivables over 5 years is $2.3 million, with a median of $2.3 million recorded in 2024.
  • Peak annual rise in Receivables hit 99.45% in 2021, while the deepest fall reached 64.49% in 2021.
  • Year by year, Receivables stood at $2.7 million in 2021, then plummeted by 34.51% to $1.8 million in 2022, then increased by 23.56% to $2.2 million in 2023, then skyrocketed by 71.3% to $3.8 million in 2024, then tumbled by 31.55% to $2.6 million in 2025.
  • Business Quant data shows Receivables for ICCC at $2.6 million in Q3 2025, $2.4 million in Q2 2025, and $3.4 million in Q1 2025.